Anastrozole Denk 1mg tablets film-coated

Negara: Armenia

Bahasa: Inggris

Sumber: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Karakteristik produk Karakteristik produk (SPC)
23-09-2022

Bahan aktif:

anastrozole

Tersedia dari:

Haupt Pharma Muenster GmbH

Kode ATC:

L02BG03

INN (Nama Internasional):

anastrozole

Dosis:

1mg

Bentuk farmasi:

tablets film-coated

Unit dalam paket:

(30/3x10/) in blister

Jenis Resep:

Prescription

Status otorisasi:

Registered

Tanggal Otorisasi:

2019-09-23

Karakteristik produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Anastrozole Denk 1 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance: anastrozole
Each film-coated tablet contains 1 mg anastrozole.
Excipients with known effect:
Each film-coated tablet contains 90 mg of lactose monohydrate and less
than 1 mmol sodium (23 mg).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
White to off-white, round, biconvex film-coated tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Anastrozole Denk 1 mg is indicated for the:

treatment of hormone receptor-positive, advanced breast cancer in
postmenopausal women.

adjuvant treatment of hormone receptor-positive, early invasive breast
cancer in postmenopausal
women.

adjuvant treatment of hormone receptor-positive, early invasive breast
cancer in postmenopausal
women already receiving adjuvant tamoxifen for 2 to 3 years.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
The recommended dose of anastrozole for adults including elderly
patients is one 1 mg tablet once
daily.
For
postmenopausal
women
with
hormone
receptor-positive,
early
invasive
breast
cancer,
the
recommended duration of adjuvant endocrine therapy is 5 years.
Special patient groups
_ _
_Paediatric population _
Anastrozole is not recommended for use in children and adolescents due
to insufficient data on safety
and efficacy (see sections 4.4 and 5.1).
_Impaired renal function _
No
dose
modification
is
recommended
for
patients
with
mild
or
moderate
renal
impairment.
Anastrozole should be used with caution in patients with severe renal
impairment (see sections 4.4 and
5.2).
_ _
_Impaired hepatic function_
No dose modification is recommended for patients with mild hepatic
impairment. Caution is advised
in patients with moderate to severe hepatic impairment (see section
4.4).
METHOD OF ADMINISTRATION
Anastrozole Denk 1 mg is taken orally.
4.3
CONTRAINDICATIONS
Anastrozole is contraindicated in:

pregnant or breastfeeding women.

hyp
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Rusia 23-09-2022

Peringatan pencarian terkait dengan produk ini